Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting April 10, 2022
Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors April 8, 2022
Affimed to Report Full Year 2021 Financial Results & Corporate Update on March 31, 2022 March 24, 2022
Affimed Announces Clinical Updates at the Annual Meeting of the American Association for Cancer Research March 8, 2022
Affimed Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers after Freezing & Thawing February 9, 2022
Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study of AFM13 in PTCL, and Provides Business Update January 6, 2022
